Profile: AMAG Pharmaceuticals Inc (AMAG.OQ)
26 Nov 2014
AMAG Pharmaceuticals, Inc., incorporated on November 9, 1981, is a specialty pharmaceutical company. The Company markets Feraheme, an iron compound for the treatment of iron deficiency anemia in adult patients, and MuGard Mucoadhesive Oral Wound Rinse, an oral rinse for treating oral mucositis. It also operates the maternal health division through its subsidiary, Lumara Health Inc. Lumara Health is a marketer of Makena(R) (hydroxyprogesterone caproate injection), which is indicated to reduce the risk of preterm birth in women who are pregnant with one baby and who have delivered one preterm baby spontaneously in the past.
Feraheme (ferumoxytol) Injection is indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD). There are two methods used to treat IDA in CKD patients: oral iron supplements and IV iron. Oral iron supplements are often not absorbed well by the gastrointestinal tract and frequently have unpleasant side effects, such as constipation, diarrhea and cramping, which can cause patients to stop taking their medication. In addition, it can take an extended time for hemoglobin levels to improve the initiation of oral iron treatment. The Company offers Feraheme to both the dialysis and non-dialysis CKD markets, including to nephrologists, hematologists, dialysis organizations, hospitals and other end-users who treat patients with CKD.
The Company competes with Fresenius Medical Care North America, American Regent Laboratories, Inc., Sanofi-Aventis U.S. LLC and Watson Pharmaceuticals, Inc.
AMAG Pharmaceuticals Inc
1100 Winter Street
WALTHAM MA 02451